Sneha Limaye

Dr. Sneha Limaye


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
VMVeena Muralidharan
Veena Muralidharan
TSThomas E. Sussan
Thomas E. Sussan
SLSneha Limaye
Sneha Limaye
KKKirsten Koehler
Kirsten Koehler
DWD'ann Williams
D'ann Williams
SBShyam Biswal
Shyam Biswal
Nearly three billion people use solid fuels for cooking and heating, which leads to extremely high levels of household air pollution and is a major cause of morbidity and mortality. Many stove manufacturers have developed alternative cookstoves (ACSs) that are aimed at reducing emissions and fuel consumption. Here, we tested a traditional clay chulha cookstove (TCS) and five commercially available ACSs, including both natural draft (Greenway Smart Stove, Envirofit PCS-1) and forced draft stoves (BioLite HomeStove, Philips Woodstove HD4012, and Eco-Chulha XXL), in a test kitchen in a rural village of western India. Compared to the TCS, the ACSs produced significant reductions in particulate matter less than 2.5 µm (PM2.5) and CO concentrations (Envirofit: 22%/16%, Greenway: 24%/42%, BioLite: 40%/35%, Philips: 66%/55% and Eco-Chulha: 61%/42%), which persisted after normalization for fuel consumption or useful energy. PM2.5 and CO concentrations were lower for forced draft stoves than natural draft stoves. Furthermore, the Philips and Eco-Chulha units exhibited higher cooking efficiency than the TCS. Despite significant reductions in concentrations, all ACSs failed to achieve PM2.5 levels that are considered safe by the World Health Organization (ACSs: 277–714 μg/m3 or 11–28 fold higher than the WHO recommendation of 25 μg/m3).

1 November 2014 in Immunology and Allergy Clinics of North America
Verified
Journal Article
Closed access
SLSneha Limaye
Sneha Limaye
SSSundeep Salvi
Sundeep Salvi

1 February 2020 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
AGAloke Ghoshal
Aloke Ghoshal
PWPradyut Waghray
Pradyut Waghray
GDGeorge Dsouza
George Dsouza
MSMahip Saluja
Mahip Saluja
MAMayank Agarwal
Mayank Agarwal
JGJaideep Gogtay
Jaideep Gogtay

1 January 2016 in Perspectives in Clinical Research
Verified
Journal Article
Open access
PDF file
SLSneha Limaye
Sneha Limaye
RKRashmi Kadam
Rashmi Kadam
SBSanghratna Borde
Sanghratna Borde
SMSapna Madas
Sapna Madas
ANAarti Nagarkar
Aarti Nagarkar
SSSundeep Salvi
Sundeep Salvi
Background: Clinical research in India experienced dramatic changes with series of stringent guidelines introduced by regulatory authorities. These guidelines posed significant challenges for the clinical trial industry. Objective: To assess the perceptions and opinion of Indian Investigators about the new regulatory guidelines. Methods: We developed a survey questionnaire on recent regulatory guidelines which was hosted on a web portal. Seventy-three investigators from India participated in the survey. Results: Central registration of Ethics Committees (ECs) was agreed by 90.1% participants, 76.8% participants agreed to compensation of subjects for study related Serious Adverse Events (SAE's). The compulsion to include government sites in clinical trials was not agreed by 49.3% participants while 21.2% agreed to it. Restriction on a number of trials per investigator was agreed by 49.3% of participants while 40.9% disagreed. Participants (50.7%) disagreed to the introduction of audio-video (AV) recording of informed consent, 36.6% agreed and 12.7% were neutral. Discussion: Participants observed that post central registration; ECs have improved systems with adequate member composition, functional Standard Operating Procedures, and timely approvals. Participants agreed that compensation of study related SAE's would assure subject protection and safety. The introduction of AV consenting was strongly debated sighting sociocultural issues in the implementation of the same. Conclusion: Participants endorsed guidelines pertaining to the central registration of ECs, SAE related compensation. Restrictions on a number of trials per investigator and AV consenting were debated ardently. The response of the survey participants who are clinical trial investigators in India showed general acceptance, effectiveness and anticipated compliance to the new regulatory guidelines.